Solid Tumors
Unleashing the potential of precision oncology
Targeted therapies are transforming the treatment of solid tumors by delivering more precise interventions with fewer side effects. Whether used alone or in combination, these molecular approaches are designed to disrupt key pathways that drive tumor growth and spread—offering the potential to improve outcomes while preserving patients’ quality of life.
We have deep experience with new approaches to precision oncology and solid tumor clinical trials, including combination immunotherapies, biomarker-driven therapies, biosimilars, antibody drug conjugates, cell and gene therapies, other small molecules, and complex study designs across all phases.
our depth of experience
In the past 5 years:
396
studies
16,497
sites worldwide
67,691
patients
Tailoring mechanisms of action (MoA) to each patient, phase by phase
Principle MoAs (total):
150
targeted therapies
34
antibody drug conjugates
3
biosimilars
17
MOAs
13
chemotherapies
167
immunotherapies
12
cell and gene therapies
Engaging with the right sites and patients from day one
When it comes to precision medicine, the ability to connect with patients through investigative sites ranks as highly as medical and operational expertise.
We engage with focus, passion and peer-to-peer scientific expertise to develop deep relationships with key opinion leaders, investigators and sites. We are the only CRO to field dedicated Research Science Liaisons for this purpose – helping you meet your recruitment targets faster, no matter how complex the trial.
Specialized support for every stage of antibody-drug conjugate development
Antibody-drug conjugates (ADCs) are revolutionizing cancer therapy by combining the precision of targeted treatment with the potency of cytotoxic agents, improving efficacy and expanding their therapeutic potential for treating hematological cancers to solid tumors.
We bring decades of deep experience and proven success in advancing ADC therapies delivering potent payloads such as DNA targeting, topisomerase inhibitors, microtubule targeting and immune targeting to treat a range of solid tumor and hematology indications. With a specialized understanding of ADC mechanisms of action and emerging ADC technologies, we are uniquely equipped to help you accelerate innovation and bring transformative cancer therapies to patients.
Advancing ADC innovation with clarity and speed
Learn how we’re working with sponsors to break barriers — from managing unexpected toxicities to accelerating timelines
Advancing innovation as a radiopharmaceutical CRO
Radiopharmaceuticals are redefining what’s possible in oncology, delivering targeted diagnostic and therapeutic solutions that direct radioactive compounds precisely to cancer cells.
We offer deep expertise in oncology and early phase oncology, marked by global scientific and regulatory expertise, strong ties with nuclear medicine investigators, and a proven track record navigating the complexities of radiopharmaceutical study design, specialized safety protocols and logistics.
We also combine our global radiopharmaceutical expertise, specialized site networks and regulatory precision to support sponsors in theranostics trials—advancing personalized oncology care through targeted diagnostics and therapeutics.
Biosimilars and bispecific antibodies
Our experience also includes the feasibility, design and execution of clinical trials investigating bi- and tri-specific antibodies and biosimilars for a range of solid tumor types.
Contact us to learn how Syneos Health can support your solid tumor clinical trial.
Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine the precision of monoclonal antibodies with the potency of cytotoxic agents. By linking these components, ADCs deliver treatment directly to cancer cells while limiting exposure to healthy tissue. This targeted approach is designed to enhance effectiveness, reduce systemic toxicity and offer new hope in hard-to-treat solid and hematologic tumors.
Radiopharmaceuticals are targeted compounds that deliver radioactive isotopes directly to cancer cells for diagnosis or treatment. In oncology, they enable highly precise imaging and therapy by binding to specific tumor markers—minimizing damage to healthy tissue. This approach supports earlier detection, more accurate staging and focused treatment for a range of solid and hematologic cancers.
Related Content
Looking for exclusive insight?
